By very careful these waters are filled with paid advocates, credentials mean nothing. What I do think however is that there is a great deal of misconception surrounding their treatments. After Judi Lecoq posted the Dr's speel there is certainly a lot of bafflegag. He clearly has found a voice through MS social media sites. My consensus is, I see desperate patients prepared to spend a great deal of money for what can only be described as some mediocre results. As more and more patients seek these treatments they develop a great awareness and understanding of the science. Still very difficult to navigate the waters but hopefully we can separate the wheat from the chaff.
Right off the bat Jennifers tale brings your attention to the fact Celltex provides higher doses of stem cells than over seas clinics, with no explanation of infusion technique. She later suggests as an added bonus it can it reduced dense breast tissue. Cancer kills about 8 mill patients a year those numbers are excepted to up to 20 mill be 2012. Breast cancer is on the rise by 25%, 100 of thousands are employed in cancer research with billions spent globally. If the type of cell infusion they offer even remotely offered any hope for cancer patients they would not waste their time chasing and treating the minnow diseases. I think Jennifer might be given consideration for that list of advocates.
These are some recent comments by Dr. Christopher Duntsch, Neurosurgeon Clinical Director at Texas Neurosurgical Institute.
“I have two decades working with ESCs, totipotent derivatives, and adult stem cells. Multi-species for neural stem cells, adipose stem cells, spinal disc stem cells, hematopoietic stem cells, totipotent multi-potential stem cells, cancer stem cells of many types, mesenchymal stem cells, bone stem cells, annulus stem cells, several others. All in the context of tissue engineering and regenerative medicine. From my experience I will share a simple observation that I have seen played out over years from many academic efforts, my own and those of many others, and from the biotech sector (cytori, or mesoblast for example). Adipose stem cells are atypical and stand out in their biology and potential against most if not all stem cells ... they are different species for lack of a better way of putting it. They can be pushed in several directions for the purposes of tissue engineering efforts. However, I have seen again and again, my own work and that of many others at academic and commercial levels, that adipose stem cells, while not an actual adipose stem cell, instead a perivascular stem cell that is related to but not directly derived from vasculature biologics or pericyte biology, are of little use when developed in the context of regenerative medicine that does not involve vasculature. If you attempt to develop a research project or program developing adipose stem cells for liver disease or spinal cord stem cell based therapeutics, etc, you will be disappointed and make little progress. If you target you efforts to the vasculature and vascular related pathology (stroke, TIA, CAD, Ischemic events, etc.), you are very likely to be rewarded with the data and the progress that you are seeking. Adipose stem cells, while I am not sure that are or are not directly derived from pericytes or even actually pericytes, or similar related to vascular biologics, are closely related in many ways functionally and biologically and are a good adult stem cell to work with for the aforementioned areas. Although my opinions are based on lots of data by many researchers and my opinions sound definitive, they are just, that opinions, and despite what you might see in the literature, be thoughtful before you commit to something that might take years, resources, and time that could be directed in several ways to a better outcome.”http://www.theguardian.com/world/2010/j ... -treatmenthttp://www.healthintheglobalvillage.com ... nspection/